Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback